10.6084/m9.figshare.11821926.v2
Hady Keita
Hady
Keita
Cleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos
Santos
Matheus Mercês Ramos
Matheus Mercês
Ramos
Elias Carvalho Padilha
Elias Carvalho
Padilha
Rodolfo Bortolozo Serafim
Rodolfo Bortolozo
Serafim
Andres Navarrete Castro
Andres Navarrete
Castro
Jesus Rafael Rodriguez Amado
Jesus Rafael Rodriguez
Amado
Gabriel Monteiro da Silva
Gabriel Monteiro
da Silva
Irlon Maciel Ferreira
Irlon Maciel
Ferreira
Silvana Giuliatti
Silvana
Giuliatti
José Carlos Tavares Carvalho
José Carlos Tavares
Carvalho
Assessment of the hypoglycemic effect of Bixin in alloxan-induced diabetic rats: <i>in vivo</i> and <i>in silico</i> studies
Taylor & Francis Group
2020
Bixin
hypoglycemia
PPARγ
in vivo
in silico
2020-02-14 06:28:23
Journal contribution
https://tandf.figshare.com/articles/journal_contribution/Assessment_of_the_hypoglycemic_effect_of_Bixin_in_Alloxan-induced_Diabetic_Rats_i_in_vivo_i_and_i_in_silico_i_studies/11821926
<p>The objectives of this study were to extract and purify Bixin from the seeds of <i>Bixa orellana</i> and to evaluate its hypoglycemic activity <i>in vivo</i>, as well as, to conduct an <i>in silico</i> study of selectivity on peroxisome proliferator-activated receptors via molecular docking and molecular dynamics simulations. Oral administration of Bixin (10 mg/kg) significantly reduced their glucose level that was alloxan-induced diabetic rats. Bixin showed <i>in silico</i> selectivity on peroxisome proliferator-activated receptors (PPARs), particularly by the peroxisome proliferator-activated receptor gamma (PPARγ), which supports the hypoglycemic activity of Bixin. From the results obtained, it can be inferred that Bixin presents hypoglycemic characteristics, which was confirmed by the results obtained from the <i>in vivo</i> and <i>in silico</i> tests. Bixin may act by other pathways to control blood glucose and thus it is possible that it presents a different toxicity profile than troglitazone, rosiglitazone and pioglitazone. However, more studies on the activity and toxicity of Bixin are needed to evaluate for further clinical use.</p> <p>Communicated by Ramaswamy H. Sarma</p>